medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-3-48-53medsovet-1749Research ArticleОСЛОЖНЕНИЯ САХАРНОГО ДИАБЕТАCOMPLICATIONS OF DIABETESРОЛЬ ГЛИКИРОВАННОГО ГЕМОГЛОБИНА В ДИАГНОСТИКЕ И УЛУЧШЕНИИ ПРОГНОЗА САХАРНОГО ДИАБЕТАTHE ROLE OF GLYCATED HEMOGLOBIN IN THE DIAGNOSIS AND IMPROVED PROGNOSIS OF DIABETES MELLITUSБирюковаЕ. В.BiryukovaE. V.

д.м.н., профессор

MD, Prof.

Московский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian Federation201730122017034853Copyright © Бирюкова Е.В., 20172017Бирюкова Е.В.Biryukova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1749

Пристальное внимание к проблеме сахарного диабета (СД) связано с растущей распространенностью заболевания и опасностью развития многочисленных сосудистых осложнений (нефропатия, ретинопатия, поражение магистральных сосудов сердца, головного мозга, периферических сосудов нижних конечностей), в развитии которых ключевое значение имеет хроническая гипергликемия. В 2011 г. ВОЗ приняла решение о возможности использования в качестве диагностического критерия СД уровня гликированного гемоглобина (HbA1c). Неоценима роль HbA1c при выборе сахароснижающей терапии. Согласно «Алгоритмам специализированной медицинской помощи больных сахарным диабетом», стратификация лечеб- ной тактики у больных с впервые установленным СД2 определяется в зависимости от исходного HbA1c [1].

The focus on the problem of diabetes mellitus (DM) is associated with the increasing prevalence of the disease and the risk for the development of many vascular complications (nephropathy, retinopathy, lesions of the great vessels of the heart, brain, peripheral vascular disease of the lower limbs), in the development of which chronic hyperglycemia plays a crucial role. In 2011, the WHO decided that glycated hemoglobin (HbA1c) could be used as the diagnostic criterion for diabetes. The role of HbA1c in the choice of hypoglycemic therapy is invaluable. According to the Algorithms of Specialized Medical Care for Diabetes Mellitus Patients, stratification of treatment strategy in patients with newly diagnosed type 2 diabetes is determined by the initial HbA1c.

сахарный диабетосложнения сахарного диабетагликированный гемоглобинdiabetes mellituscomplications of diabetesglycated hemoglobinReferencesАлгоритмы специализированной медицинской помощи больных сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, 7-й выпуск, Москва, 2015.Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, 7-й выпуск, Москва, 2015.Багаев А.В. Лабораторные методы определения гликированного гемоглобина. Клинико-лабораторный консилиум, 2009, 3: 88-92.Багаев А.В. Лабораторные методы определения гликированного гемоглобина. Клинико-лабораторный консилиум, 2009, 3: 88-92.Дедов И.И., Шестакова М.В. Проблемы контроля качества диабетологической службы в России по данным на январь 2007 г. Сахарный диабет, 2007, 3: 55-7.Дедов И.И., Шестакова М.В. Проблемы контроля качества диабетологической службы в России по данным на январь 2007 г. Сахарный диабет, 2007, 3: 55-7.Дедов И.И., Шестакова М.В., Галстян Г.Р. Распро страненность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет, 2016, 19(2): 104-112.Дедов И.И., Шестакова М.В., Галстян Г.Р. Распро страненность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет, 2016, 19(2): 104-112.Сахарный диабет: диагностика, лечение, профилактика. Под редакцией И.И. Дедова, М.В. Шестакова М.В. М.: ООО «Издательство «МИА», 2011. 808 с.Сахарный диабет: диагностика, лечение, профилактика. Под редакцией И.И. Дедова, М.В. Шестакова М.В. М.: ООО «Издательство «МИА», 2011. 808 с.Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellituspresent and future perspectives. Nat Rev Endocrinol, 2012, 8: 228-236.Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellituspresent and future perspectives. Nat Rev Endocrinol, 2012, 8: 228-236.Cohen RM, Smith EP. Frequency of HbA1c discordance in estimating blood glucose control. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11: 512-517.Cohen RM, Smith EP. Frequency of HbA1c discordance in estimating blood glucose control. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11: 512-517.Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA1c Affected by Glycemic Instability. Diabetes Care, 2003, 26(10): 2728-2733. doi: 10.2337/diacare.26.10.2728.Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA1c Affected by Glycemic Instability. Diabetes Care, 2003, 26(10): 2728-2733. doi: 10.2337/diacare.26.10.2728.Duckworth W, Abraira C, Moritz T et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med, 2009, 360: 129-39.Duckworth W, Abraira C, Moritz T et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med, 2009, 360: 129-39.Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N. Engl. J. Med., 2008, 358: 2630-3.Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N. Engl. J. Med., 2008, 358: 2630-3.Gerstein HC, Miller ME, Byington RP et al. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358: 2545–59.Gerstein HC, Miller ME, Byington RP et al. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358: 2545–59.Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 3(58): 2545–59.Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 3(58): 2545–59.Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359: 1577-89.Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359: 1577-89.The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med., 1993, 329(14): 977–986.The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med., 1993, 329(14): 977–986.International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org.International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org.Kim C, Bullard KM, Herman WH, Beckles GL, Kim C, Bullard KM, Herman WH and Beckles GL. Association between iron deficiency and A1C levels among adults without diabetes in the national health and nutrition examination survey, 1999–2006. Diabetes Care, 2010, 33: 780-785. doi:10.2337/dc09-0836Kim C, Bullard KM, Herman WH, Beckles GL, Kim C, Bullard KM, Herman WH and Beckles GL. Association between iron deficiency and A1C levels among adults without diabetes in the national health and nutrition examination survey, 1999–2006. Diabetes Care, 2010, 33: 780-785. doi:10.2337/dc09-0836Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. NGSP Steering Committee. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem, 2001, 47(11): 1985–1992.Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. NGSP Steering Committee. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem, 2001, 47(11): 1985–1992.Massi-Benedetti M. The Cost of Diabetes in Europe – Type II: the CODE-2 Study. Diabetolody, 2002, 45(7): S1-4.Massi-Benedetti M. The Cost of Diabetes in Europe – Type II: the CODE-2 Study. Diabetolody, 2002, 45(7): S1-4.Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care, 2003, 26(3): 881–885.Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care, 2003, 26(3): 881–885.Nathan DM, and for the DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epide miology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care, 2014, 37: 9-16. https://doi.org/10.2337/dc13-2112.Nathan DM, and for the DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epide miology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care, 2014, 37: 9-16. https://doi.org/10.2337/dc13-2112.Patel A, MacMahon S, Chalmers J, Neal B, et al. ADVANCE Collaborative Group.. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med,2008, 358: 2560-72.Patel A, MacMahon S, Chalmers J, Neal B, et al. ADVANCE Collaborative Group.. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med,2008, 358: 2560-72.Ray KK, Rao S, Seshasai K et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 2009, 373: 1765-72.Ray KK, Rao S, Seshasai K et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 2009, 373: 1765-72.Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med, 2004, 141: 421-431.Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med, 2004, 141: 421-431.Standards of Medical Care in Diabetes – 2011. Diabetes Care, 2011, 34(1): S13.Standards of Medical Care in Diabetes – 2011. Diabetes Care, 2011, 34(1): S13.Shaklai N, Garlick RL, Bunn HF. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem, 1984, 259(6): 3812–3817.Shaklai N, Garlick RL, Bunn HF. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem, 1984, 259(6): 3812–3817.Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetesprospective observation study. BMJ, 2000 Aug 12, 321(7258): 405-412.Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetesprospective observation study. BMJ, 2000 Aug 12, 321(7258): 405-412.Shah AS, Dolan LM, Kimball TR et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab., 2009, 94(10): 3740–3745.Shah AS, Dolan LM, Kimball TR et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab., 2009, 94(10): 3740–3745.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352: 837-53.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352: 837-53.Weykamp C, John WG, Mosca A. A Review of the Challenge in Measuring Hemoglobin A1c. J Diabetes Sci Technol, 2009, 3(3): 439-445.Weykamp C, John WG, Mosca A. A Review of the Challenge in Measuring Hemoglobin A1c. J Diabetes Sci Technol, 2009, 3(3): 439-445.Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci, 2010, 1212(1): 29–40.Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci, 2010, 1212(1): 29–40.

The authors declare that there are no conflicts of interest present.